Tarek M Meniawy

List of Publications by Year
in descending order

39 papers	1,519 citations	393982 19 h-index	344852 36 g-index
42 all docs	42 docs citations	42 times ranked	2610 citing authors

#	Article	IF	Citations
1	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015, 6, 42008-42018.	0.8	278
2	Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax, 2014, 69, 895-902.	2.7	128
3	A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. Journal of Thoracic Oncology, 2016, 11, 573-582.	0.5	126
4	Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. Cancer Letters, 2020, 468, 59-71.	3.2	113
5	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer, 2018, 18, 726.	1.1	77
6	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 2019, 154, 441-448.	0.6	74
7	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. Journal of Clinical Oncology, 2022, 40, 762-771.	0.8	71
8	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. , 2021, 9, e002255.		61
9	PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. Oncologist, 2020, 25, e520-e527.	1.9	54
10	Combined ipilimumab and nivolumab firstâ€line and after BRAFâ€targeted therapy in advanced melanoma. Pigment Cell and Melanoma Research, 2020, 33, 358-365.	1.5	51
11	Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).. Journal of Clinical Oncology, 2019, 37, 5501-5501.	0.8	46
12	Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget, 2017, 8, 67355-67368.	0.8	45
13	Locusâ€specific concordance of genomic alterations between tissue and plasma circulating tumor <scp>DNA</scp> in metastatic melanoma. Molecular Oncology, 2019, 13, 171-184.	2.1	44
14	Sensitive droplet digital PCR method for detection of <i>TERT</i> promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 2017, 8, 78890-78900.	0.8	44
15	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 2020, 26, 5926-5933.	3.2	41
16	Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. British Journal of Cancer, 2020, 122, 1059-1067.	2.9	41
17	Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. Clinical Cancer Research, 2019, 25, 1472-1478.	3.2	38
18	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. Lung Cancer, 2016, 93, 9-16.	0.9	27

#	Article	IF	Citations
19	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget, 2019, 10, 113-122.	0.8	23
20	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 3013-3013.	0.8	20
21	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. British Journal of Cancer, 2022, 126, 401-408.	2.9	18
22	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. Scientific Reports, 2021, 11, 15312.	1.6	15
23	A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.. Journal of Clinical Oncology, 2022, 40, 1021-1021.	0.8	15
24	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapiesâ€"Beyond BRAF Mutant Detection. Cancers, 2020, 12, 3793.	1.7	12
25	IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.. Journal of Clinical Oncology, 2022, 40, 5515-5515.	0.8	9
26	AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 2583-2583.	0.8	8
27	Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients. Cancers, 2021, 13, 6225.	1.7	8
28	A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, e17049-e17049.	0.8	6
29	Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 2020, 11, 4016-4027.	0.8	6
30	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. Journal of Gynecologic Oncology, 2021, 32, e95.	1.0	5
31	Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. International Journal of Gynecological Cancer, 2022, 32, 560-565.	1.2	4
32	A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 3066-3066.	0.8	3
33	Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, TPS3113-TPS3113.	0.8	3
34	Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 2551-2551.	0.8	2
35	Ipilimumab- and nivolumab-associated enterocolitis with florid necrotising granulomatous inflammation: a novel manifestation of â€˜immunomodulatoryâ€™ enterocolitis. Pathology, 2018, 50, 466-469.	0.3	1
36	A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert Review of Anticancer Therapy, 2021, 21, 465-474.	1.1	1

#	Article	IF	Citations
37	Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).. Journal of Clinical Oncology, 2021, 39, 5584-5584.	0.8	1
38	Patient human leukocyte antigen (HLA) genotype may predict response to anti-programmed death receptor 1 (anti-PD1) in advanced melanoma.. Journal of Clinical Oncology, 2021, 39, e21512-e21512.	0.8	0
39	Autoantibodies as potential biomarkers of immune-related adverse events in patients with advanced cutaneous melanoma treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2022, 40, 9536-9536.	0.8	0